Clinical Study of Active Intervention in High-risk HFpEF Patients

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorXiangtan Central Hospital

About this trial

Based on inclusion and exclusion criteria, this experiment plans to include 924 Heart Failure with Preserved Ejection Fraction(HFpEF) patients with increased risk of all-cause death. The enrolled patients will divided into usual care group (n=462) and targeted intervention group (n=462) in a 1:1 ratio. The usual care patients will receive routine heart failure treatment. Patients in targeted intervention group, on top of routine therapy for heart failure, will receive further therapy targeting therapy to correct hypoalbuminemia, anemia or hyponatremia, and try to enhance medication to lower N-terminal pro brain natriuretic peptide (NT-proBNP), C-reactive protein(CRP), New York Heart Association(NYHA )Classification, to add diuretics for patients with higher right ventricular diameters(RADs),multidiscipline intervention for patients complicating chronic obstructive pulmonary disease(COPD), and actively reperfusion for ischemic HFpEF patients. The incidence of all-cause death will be compared after 3 years follow-up.The primary endpoint is the occurrence of all-cause mortality events during the follow-up period.

Eligibility criteria

Qualifiers

Discharged HFpEF patients with risk score > or equal 200.37.

Disqualifiers

Patients with a life expectancy of less than 1-year due to malignancy.

Trial design

Treatments tested in this trial

  • Targeted intervention based on risk factors

Treatment groups

924 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Xiangtan Central Hospital

Lead sponsor

The First People's Hospital of Xiangtan City

Collaborator

The Xiangtan People's Hospital

Collaborator

The Xiangxiang People's Hospital

Collaborator